• June 3-6, 2024
  • San Diego Convention Center, California



Olatec Therapeutics

Tuesday, June 04, 2024
Company Presentation
Company Presentation Theater 3
Olatec is a privately-owned biotech company leading the clinical development of oral, first-in-class anti-inflammatory drugs for acute and chronic indications. The lead compound, dapansutrile, is a specific inhibitor of the NLRP3 inflammasome, and inhibits the production of IL-1β, a prototypical inflammatory mediator of innate immunity. Olatec’s dapansutrile is a leader in the clinical development of the NLRP3 class. Several precedent activities involving acquisitions of other selective NLRP3 inhibitor companies are leading the interest from partners in the NLRP3 space. Recent partnerships and acquisitions publicly announced in the space include: • Ventus Therapeutics & Novo Nordisk - licensing of preclinical compound for $70 million up front • Roche acquired Inflazome Ltd. for $450 million - • Novartis IFM Tre for $310 million upfront -
Olatec Therapeutics
Company Website: http://www.olatec.com
Lead Product in Development: dapansutrile
Number Of Unlicensed Products (For Which You Are Seeking Partners): 1

Company HQ City

New York

Company HQ State

New York

Company HQ Country

United States

CEO/Top Company Official

Ms. Damaris Skouras

Development Phase of Primary Product

Phase II
Primary Speaker
Mustafa Noor, MD
Chief Medical Officer
Olatec Theapeutics
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.